Mindblown: a blog about philosophy.
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Catalent delays quarterly filing with SEC on $700 million impairment charge
(Reuters) – Catalent (NYSE:CTLT) will delay its quarterly filing with the U.S. securities regulator due to a goodwill impairment charge of about $700 million related to acquisitions in the company’s consumer health and biomodalities unit, the company said late Monday. The contract drug manufacturer, whose annual results were delayed several times this year to account […]
Got any book recommendations?